JP5268222B2 - 改変された糖類、それらの結合体、およびそられの製造 - Google Patents

改変された糖類、それらの結合体、およびそられの製造 Download PDF

Info

Publication number
JP5268222B2
JP5268222B2 JP2004532625A JP2004532625A JP5268222B2 JP 5268222 B2 JP5268222 B2 JP 5268222B2 JP 2004532625 A JP2004532625 A JP 2004532625A JP 2004532625 A JP2004532625 A JP 2004532625A JP 5268222 B2 JP5268222 B2 JP 5268222B2
Authority
JP
Japan
Prior art keywords
capsular saccharide
capsular
saccharide
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004532625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006511465A (ja
JP2006511465A5 (enExample
Inventor
アルド ジャノッツィ，
ジョバンニ アベラニ，
フランチェスコ ノレッリ，
パオロ コスタンティーノ，
Original Assignee
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル filed Critical ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル
Publication of JP2006511465A publication Critical patent/JP2006511465A/ja
Publication of JP2006511465A5 publication Critical patent/JP2006511465A5/ja
Application granted granted Critical
Publication of JP5268222B2 publication Critical patent/JP5268222B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2004532625A 2002-08-30 2003-09-01 改変された糖類、それらの結合体、およびそられの製造 Expired - Fee Related JP5268222B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0220198.6 2002-08-30
GBGB0220198.6A GB0220198D0 (en) 2002-08-30 2002-08-30 Modified saccharides,conjugates thereof and their manufacture
PCT/IB2003/004194 WO2004019992A1 (en) 2002-08-30 2003-09-01 Modified saccharides, conjugates thereof, and their manufacture

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011228229A Division JP5314745B2 (ja) 2002-08-30 2011-10-17 改変された糖類、それらの結合体、およびそられの製造

Publications (3)

Publication Number Publication Date
JP2006511465A JP2006511465A (ja) 2006-04-06
JP2006511465A5 JP2006511465A5 (enExample) 2006-10-05
JP5268222B2 true JP5268222B2 (ja) 2013-08-21

Family

ID=9943241

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004532625A Expired - Fee Related JP5268222B2 (ja) 2002-08-30 2003-09-01 改変された糖類、それらの結合体、およびそられの製造
JP2011228229A Expired - Fee Related JP5314745B2 (ja) 2002-08-30 2011-10-17 改変された糖類、それらの結合体、およびそられの製造

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011228229A Expired - Fee Related JP5314745B2 (ja) 2002-08-30 2011-10-17 改変された糖類、それらの結合体、およびそられの製造

Country Status (16)

Country Link
US (2) US8895516B2 (enExample)
EP (1) EP1534342B1 (enExample)
JP (2) JP5268222B2 (enExample)
CN (2) CN101863998B (enExample)
AT (1) ATE319481T1 (enExample)
AU (1) AU2003260921B2 (enExample)
BR (1) BR0314089A (enExample)
CA (1) CA2497167C (enExample)
DE (1) DE60303961T2 (enExample)
DK (1) DK1534342T3 (enExample)
ES (1) ES2260682T3 (enExample)
GB (1) GB0220198D0 (enExample)
MX (1) MXPA05002315A (enExample)
NZ (1) NZ538703A (enExample)
RU (2) RU2005108992A (enExample)
WO (1) WO2004019992A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
PT2191844E (pt) 2003-01-30 2014-06-04 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
WO2005051429A2 (en) * 2003-11-19 2005-06-09 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeted conjugates with a modified saccharide linker
EP1885734B1 (en) * 2005-05-06 2015-01-14 Novartis AG Immunogens for meningitidis-a vaccines
HUE032903T2 (hu) * 2005-12-22 2017-11-28 Glaxosmithkline Biologicals Sa Streptococcus pneumoniae kapszulárispoliszacharid-konjugátumok
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
AU2014200640B2 (en) * 2007-01-11 2016-06-16 Glaxosmithkline Biologicals Sa Modified saccharides
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US9475864B2 (en) 2008-09-05 2016-10-25 University Of Massachusetts Methods, compositions and vaccines relating to Neisseria meningitidis antibodies
PL2445522T3 (pl) 2009-06-22 2018-01-31 Wyeth Llc Kompozycje immunogenne antygenów Staphylococcus aureus
SG177310A1 (en) 2009-06-22 2012-02-28 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
SI2493498T1 (sl) * 2009-10-30 2017-07-31 Glaxosmithkline Biologicals Sa Čiščenje kapsularnih saharidov Staphylococcusa aureusa tipa 5 in tipa 8
SI2608805T2 (sl) 2010-08-23 2025-09-30 Wyeth Llc Stabilne formulacije antigenov rLP2086 neisserie meningitidis
BR112013005329A2 (pt) 2010-09-10 2017-05-02 Wyeth Llc variantes não lipidadas de antígenos orf2086 de neisseria meningitidis
MX2018011291A (es) 2012-03-09 2023-01-31 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
US10668164B2 (en) * 2014-02-14 2020-06-02 Pfizer Inc. Immunogenic glycoprotein conjugates
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2017158480A1 (en) * 2016-03-15 2017-09-21 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel polysaccharide-protein conjugates and process to obtain thereof
AU2017321863B2 (en) 2016-09-02 2024-07-11 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR20240011879A (ko) 2017-02-24 2024-01-26 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체의 면역원성의 증진
JP7218358B2 (ja) 2017-09-07 2023-02-06 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用
US11395849B2 (en) 2017-09-07 2022-07-26 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
WO2020182635A1 (en) * 2019-03-08 2020-09-17 Glaxosmithkline Biologicals Sa Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2427341A1 (fr) * 1978-06-02 1979-12-28 Delalande Sa Nouveaux derives aminoglycosidiques hemisynthetiques, leur procede de preparation et leur application en therapeutique
DE69104877T2 (de) * 1990-03-15 1995-03-16 Tanabe Seiyaku Co Polysulfat eines Cyclodextrinderivates und Verfahren zu dessen Herstellung.
WO1995018144A1 (en) * 1993-12-28 1995-07-06 Pfizer Inc. Steroidal glycosides
CA2189356A1 (en) * 1994-05-02 1995-11-09 Ting Chi Wong Process for preparation of glycosides of tumor-associated carbohydrate antigens
DK0959905T3 (da) * 1997-01-21 2010-04-06 Sanofi Pasteur Polysaccharid-peptid-konjugater
CA2266718C (en) * 1997-08-08 2007-05-22 Behringwerke Aktiengesellschaft Polysaccharide conjugates of biomolecules
US5929049A (en) * 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
US5952454A (en) * 1997-12-12 1999-09-14 The United States Of America As Represented By The Department Of Health And Human Services Linking compounds useful for coupling carbohydrates to amine-containing carriers
BR0308768A (pt) 2002-03-26 2005-02-15 Chiron Srl Sacarìdeos modificados possuindo estabilidade melhorada em água
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture

Also Published As

Publication number Publication date
ES2260682T3 (es) 2006-11-01
CA2497167C (en) 2011-07-12
NZ538703A (en) 2006-09-29
RU2531909C2 (ru) 2014-10-27
RU2005108992A (ru) 2005-11-10
US20060263390A1 (en) 2006-11-23
JP2012017342A (ja) 2012-01-26
BR0314089A (pt) 2005-11-16
ATE319481T1 (de) 2006-03-15
MXPA05002315A (es) 2005-06-08
JP2006511465A (ja) 2006-04-06
JP5314745B2 (ja) 2013-10-16
CN1688343A (zh) 2005-10-26
DE60303961D1 (de) 2006-05-04
EP1534342A1 (en) 2005-06-01
DK1534342T3 (da) 2006-07-10
RU2008150551A (ru) 2010-06-27
CN101863998B (zh) 2012-08-29
US20150166593A1 (en) 2015-06-18
CN1688343B (zh) 2010-09-08
WO2004019992A1 (en) 2004-03-11
CA2497167A1 (en) 2004-03-11
GB0220198D0 (en) 2002-10-09
AU2003260921B2 (en) 2008-03-06
AU2003260921A1 (en) 2004-03-19
EP1534342B1 (en) 2006-03-08
US8895516B2 (en) 2014-11-25
CN101863998A (zh) 2010-10-20
DE60303961T2 (de) 2006-10-26

Similar Documents

Publication Publication Date Title
JP5314745B2 (ja) 改変された糖類、それらの結合体、およびそられの製造
JP5380111B2 (ja) 莢膜性多糖類の可溶化および組合せワクチン
JP5361767B2 (ja) 水中において改善された安定性を持つ修飾糖
JP5038136B2 (ja) サッカリド抗原のためのグリコセラミドアジュバント
JP4696260B2 (ja) キトサンアジュンバントおよび髄膜炎菌抗原を用いる粘膜ワクチン
JP2010209122A (ja) キトサンアジュンバントおよび髄膜炎菌抗原を用いる粘膜ワクチン
AU2011226160A1 (en) Conjugation process of bacterial polysaccharides to carrier proteins
CN100491403C (zh) 具有改善的水中稳定性的修饰的糖类
WO2024110827A1 (en) Methods for preparing conjugated capsular saccharide antigens and uses thereof
JP2006516609A (ja) 粘膜髄膜炎菌性ワクチン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100519

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100818

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100921

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101019

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111017

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20111129

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20111222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121102

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121130

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130408

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130507

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

LAPS Cancellation because of no payment of annual fees